A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Trial Profile

A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Cabozantinib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Apr 2015 Primary endpoint (Progression-free survival) has not been met, according to Exelixis first quarter 2015 financial report.
    • 20 Mar 2015 Planned End Date changed to 1 Aug 2016 as reported by ClinicaTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top